STOCK TITAN

Milestone Pharmaceuticals Inc - MIST STOCK NEWS

Welcome to our dedicated news page for Milestone Pharmaceuticals (Ticker: MIST), a resource for investors and traders seeking the latest updates and insights on Milestone Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Milestone Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Milestone Pharmaceuticals's position in the market.

Rhea-AI Summary
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) plans to resubmit the NDA for etripamil to the FDA for PSVT treatment following a Refusal to File letter. The company will restructure data sets and reformat files based on FDA guidance. No additional clinical trials are required. Cash conservation measures will fund operations until mid-2025, with potential $75 million payment upon FDA approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
24.12%
Tags
none
-
Rhea-AI Summary
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) for self-administered etripamil nasal spray for the treatment of paroxysmal supraventricular tachycardia (PSVT).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-30.9%
Tags
none
-
Rhea-AI Summary
Milestone Pharmaceuticals Inc. (MIST) to Participate in Fireside Chat at Piper Sandler 35th Annual Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.16%
Tags
conferences
Rhea-AI Summary
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) submits New Drug Application for CARDAMYSTâ„¢ nasal spray to treat PSVT and reports positive Phase 2 data for etripamil in AFib-RVR. The company plans to host an Investor and Analyst Webcast to review the ReVeRA Phase 2 study results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.59%
Tags
earnings
-
Rhea-AI Summary
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) announced positive Phase 2 data for etripamil nasal spray, showing a statistically significant reduction in ventricular rate by 30 beats per minute for episodes of atrial fibrillation with rapid ventricular rate compared to placebo. The results support further clinical development in a Phase 3 trial for the management of AFib-RVR. Safety and tolerability data were generally consistent with previous studies, indicating potential for self-administered etripamil for AFib-RVR treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
Rhea-AI Summary
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) will host a virtual investor and analyst webcast on November 13, 2023, focusing on the results from the ReVeRA Phase 2 study of investigational new drug etripamil in patients with atrial fibrillation with rapid ventricular rate. Key opinion leaders, including A. John Camm, MD, and Sean Pokorney, MD, will join the webcast.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.39%
Tags
conferences clinical trial
Rhea-AI Summary
Milestone Pharmaceuticals has submitted a New Drug Application (NDA) to the FDA for etripamil nasal spray to treat PSVT. The company believes etripamil is twice as effective and three times as fast as a placebo in restoring normal heart rhythm. If approved, it will be the first rapid and reliable option for treating serious heart arrhythmias.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.69%
Tags
none
-
Rhea-AI Summary
Milestone Pharmaceuticals grants equity awards to new hires
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.23%
Tags
none
-
Rhea-AI Summary
Milestone Pharmaceuticals to present results of etripamil study at AHA Scientific Sessions 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.67%
Tags
none
Rhea-AI Summary
Milestone Pharmaceuticals Inc. to participate in fireside chat at H.C. Wainwright 25th Annual Global Investment Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.7%
Tags
conferences
Milestone Pharmaceuticals Inc

Nasdaq:MIST

MIST Rankings

MIST Stock Data

73.66M
29.74M
1%
53.42%
1.21%
Medicinal and Botanical Manufacturing
Manufacturing
Link
Canada
Montreal

About MIST

milestone pharmaceuticals is a biotechnology company located in 6100 royalmount ave, montreal, qc, canada.